James O. Armitage mostly deals with Lymphoma, Internal medicine, Surgery, Pathology and Transplantation. His Lymphoma study combines topics in areas such as Peripheral T-cell lymphoma, Survival analysis and Chemotherapy. His studies in Internal medicine integrate themes in fields like Gastroenterology and Oncology.
His work investigates the relationship between Oncology and topics such as Rituximab that intersect with problems in CHOP. The study incorporates disciplines such as Bone marrow and Carmustine in addition to Transplantation. His Diffuse large B-cell lymphoma study incorporates themes from Cancer research, Gene expression profiling, Germinal center, B cell and Aggressive lymphoma.
James O. Armitage focuses on Internal medicine, Lymphoma, Oncology, Surgery and Pathology. He has included themes like Gastroenterology and Immunology in his Internal medicine study. His Lymphoma study frequently draws connections between adjacent fields such as Disease.
His Oncology research is multidisciplinary, relying on both Combination chemotherapy, CHOP, Hodgkin lymphoma, Salvage therapy and Radiation therapy. His research investigates the connection between Surgery and topics such as Bone marrow that intersect with problems in Haematopoiesis. His Pathology study combines topics in areas such as Peripheral T-cell lymphoma, Immunophenotyping, Survival analysis and Cytogenetics.
Internal medicine, Oncology, Lymphoma, Surgery and Pathology are his primary areas of study. In his study, Multiple myeloma and Stem cell is inextricably linked to Transplantation, which falls within the broad field of Oncology. Within one scientific family, James O. Armitage focuses on topics pertaining to Chemotherapy under Lymphoma, and may sometimes address concerns connected to Anthracycline.
His work on Overall survival as part of general Surgery research is frequently linked to Surveillance, Epidemiology, and End Results, bridging the gap between disciplines. His work deals with themes such as Gastroenterology, Immunophenotyping and BCL6, which intersect with Pathology. As part of one scientific family, James O. Armitage deals mainly with the area of Diffuse large B-cell lymphoma, narrowing it down to issues related to the Cancer research, and often B cell.
James O. Armitage mainly focuses on Lymphoma, Internal medicine, Oncology, Pathology and Surgery. His Lymphoma research incorporates themes from Survival analysis and Disease. His work in Internal medicine tackles topics such as Gastroenterology which are related to areas like Follicular lymphoma, Peripheral T-cell lymphoma and Serum lactate dehydrogenase level.
His Oncology research integrates issues from Myeloid, Regimen, Radiation therapy and Nuclear medicine. His Blastoid study, which is part of a larger body of work in Pathology, is frequently linked to Statistical analysis, bridging the gap between disciplines. James O. Armitage interconnects Brentuximab vedotin, Radiology, Cumulative incidence and Confidence interval in the investigation of issues within Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos.
A predictive model for aggressive non-Hodgkin's lymphoma
M. A. Shipp;D. P. Harrington;J. R. Anderson;J. O. Armitage.
The New England Journal of Medicine (1993)
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
Andreas Rosenwald;George Wright;Wing C. Chan;Wing C. Chan;Joseph M. Connors.
The New England Journal of Medicine (2002)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans;Dennis D. Weisenburger;Timothy C. Greiner;Randy D. Gascoyne.
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
B D Cheson;S J Horning;B Coiffier;M A Shipp.
Journal of Clinical Oncology (1999)
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
James O. Armitage.
Stromal gene signatures in large-B-cell lymphomas
G Lenz;G Wright;S S Dave;W Xiao.
The New England Journal of Medicine (2008)
New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
James O. Armitage;Dennis D. Weisenburger.
Journal of Clinical Oncology (1998)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave;George Wright;Bruce Tan;Andreas Rosenwald;Andreas Rosenwald.
The New England Journal of Medicine (2004)
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*
Thomas J. Smith;Howard Ozer;Langdon L. Miller;Charles A. Schiffer.
Journal of Clinical Oncology (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: